Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors.
Kim C, Wang XD, Liu Z, Hao J, Wang S, Li P, Zi Z, Ding Q, Jang S, Kim J, Luo Y, Huffman KE, Pal Choudhuri S, Del Rio S, Cai L, Liang H, Drapkin BJ, Minna JD, Yu Y.
Kim C, et al. Among authors: li p.
Sci Adv. 2024 Jan 19;10(3):eadh2579. doi: 10.1126/sciadv.adh2579. Epub 2024 Jan 19.
Sci Adv. 2024.
PMID: 38241363
Free PMC article.